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Innate lymphoid cells are central to the regulation of immunity at mucosal barrier sites, with group 2 innate lymphoid cells
(ILC2s) being particularly important in type 2 immunity. In this study, we demonstrate that microRNA(miR)-142 plays a critical,
cell-intrinsic role in the homeostasis and function of ILC2s. Mice deficient for miR-142 expression demonstrate an ILC2
progenitorbiased development in the bone marrow, and along with peripheral ILC2s at mucosal sites, these cells display a
greatly altered phenotype based on surface marker expression. ILC2 proliferative and effector functions are severely
dysfunctional following Nippostrongylus brasiliensis infection, revealing a critical role for miR-142 isoforms in ILC2-mediated
immune responses. Mechanistically, Socs1 and Gfi1 expression are regulated by miR-142 isoforms in ILC2s, impacting ILC2
phenotypes as well as the proliferative and effector capacity of these cells. The identification of these novel pathways opens
potential new avenues to modulate ILC2-dependent immune functions. The Journal of Immunology, 2021, 206: 27252739.
I nnate lymphoid cells (ILCs) play critical roles in an array ofbiological processes, particularly at mucosal barrier sites. How-ever, dysregulation of ILC activity also contributes to the onset
of chronic inflammatory and autoimmune diseases such as inflam-
matory bowel disease, asthma, allergy, and atopic dermatitis (1).
ILCs can be classified into subsets, which reflect those of an ab
T cell paradigm. Group 1 ILCs include NK cells and helper-like
ILC1s, which are critical innate producers of molecules such as
IFN-g and TGFb (2). These cells are the innate equivalents of
CD81 T cells and CD41 Th1 cells, respectively. Group 3 ILCs ex-
press RORgt and include lymphoid tissue inducer cells as well as
NK cell receptorexpressing (NCR1 ILC3) or negative
(NCRILC3) subsets, which express IL-17 and IL-22, like CD41
Th17. Group 2 ILCs (ILC2s), are reliant on a number of transcrip-
tion factors, including GATA3 (3, 4), growth factor independent 1
(GFI1) (5), RORa (6) and T cell factor 1 (TCF1) (7). They express
receptors for epithelial-derived cytokines including IL-33, IL-25,
and among a growing number of recognized functions, contribute to
type 2 immune responses via the expression of cytokines such as
IL-5, IL-13, IL-4, and IL-9, similar to Th2 cells.
Like other helper-like ILC subsets, ILC2s are lineage-negative
cells expressing IL-7Ra (CD127). These cells express an array of
characteristic surface markers, including (but not limited to) Klrg1,
Icos, IL-2Ra (CD25), c-Kit, and Sca-1, which aid their identifica-
tion by immunophenotyping. However, the expression pattern of
these markers may alter depending on the tissue in which the cells
are resident (8) and may be highly dynamic in response to activation
state (9). In mice for example, Klrg1 is expressed by nearly all
ILC2s in the intestinal lamina propria and acts as a robust marker of
ILC2s at this site, whereas expression of this marker at
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immunological baseline is lower in other sites such as the lung (8).
Heterogeneity within the ILC2 pool has also been noted, corre-
sponding to differences in expression profiles of phenotypic
markers. For instance, in the murine lung and fat-associated lym-
phoid tissue, “natural” ILC2s are predominantly IL-33responsive
ILC2s that lack or have limited expression of the receptor for IL-25
(IL-25R) and demonstrate low expression of Klrg1, relative to
“inflammatory” ILC2s (iILC2s) (10). iILC2s are Klrg1hi cells that
highly express IL-25R but lack expression of the IL-33 receptor
(ST2). These cells accumulate after exposure to IL-25 and during im-
mune responses directed by parasitic worms. iILC2 can also take on
an ILC3-like profile, gaining the capacity for IL-17A expression in
response to fungal infections such as Candida albicans (10).
Although ILC subsets functionally mirror those of ab-T cells, the
early pathways that regulate their development diverge downstream
of the bone marrow (BM)common lymphoid progenitor shared by
both lineages. All murine ILCs arise from multipotent early innate
lymphoid progenitors (11) and CD1271a4b71 a-lymphoid progen-
itors (aLP). Differentiation of an inhibitor of DNA-binding
2dependent common progenitor to all helper-like ILC subsets
(ChILP), which has lost the potential for NK cell development, oc-
curs downstream of these progenitor populations (12). From the
ChILP, cells expressing transcription factor PLZF form the earliest
fully committed helper-like ILC precursor (ILCp) populations, capa-
ble of differentiating into helper ILC1, ILC2, and ILC3 subsets,
whereas PLZF ChILP give rise to CCR61 lymphoid tissue inducer
cellexpressing RORgt (13). Expression of programmed death re-
ceptor 1 (Pd-1) within the ChILP pool has been previously shown
to faithfully correlate with expression of PLZF (14). An additional
progenitor within the ILCp can be further identified, which appears
to only hold potential for development into the ILC2 subset and is
referred to as the ILC2 progenitor (ILC2p) (3, 14, 15).
MicroRNAs (miRs) are noncoding RNAs, which maintain cell
typespecific transcriptomes by posttranscriptionally regulating
gene expression. This is primarily achieved by binding of the miR
seed region situated at the 59 end of the mature miR strand, with
complementary sites in the 39 untranslated region (UTR) of the tar-
get transcript. Of the miRs found in hematopoietically derived cell
types, miR-142 is particularly highly and ubiquitously expressed
(16). Expression of miR-142 occurs as two mature isoforms,
miR-142-3p and miR-142-5p, synthesized by differential processing
of the miR-142 precursor hairpin, derived from a single, highly
evolutionarily conserved locus. Within the immune system, miR-
142 plays profound and nonredundant roles in multiple facets of
immune cell development, fate, and function (1722). This is con-
cordant with reported aberrations in miR-142 expression during im-
mune-pathologies (2327) and with its critical role in the
maintenance of peripheral immune tolerance (28, 29). Importantly,
miR-142 expression in lymphocytes such as T cells has been associat-
ed with anti-inflammatory actions, with downregulation of expression
observed in association with activated cell phenotypes (23, 30). Re-
cently, it has been demonstrated that expression of miR-142 isoforms
play important roles in the homeostasis of group 1 ILCs (31). Howev-
er, how miR-142 regulates other helper ILC subsets is unknown.
In this study, we extend the understanding of the roles of miR-
142 in immune system function by revealing that ILC2 homeostasis




Mir142/, Mir142fl/flCD4cre1, and Mir142fl/flERT2Cre mice were generated
and maintained as previously described (28, 29). The B6-Mir142em2Card
strain carries a 26-bp deletion of the miR-142-3p sequence generated using
CRISPR-Cas9 by the Centre for Animal Resources and Development, Ku-
mamoto University. Rag1/ mice were bred at King’s College London and
Rag1/Mir142/ mice were generated by in-house breeding of Mir142/
and Rag1/ lines. C57BL/6J wild-type (WT) mice were purchased from
Charles River, U.K. Cd4Cre mice were kindly provided by Professor Mat-
thias Merkenschlager (Medical Research Council London Institute of Medi-
cal Sciences, Imperial College London, U.K.). Tamoxifen-inducible, Rosa26-
Cre recombinase (Rosa26-Cre-ERT2)transgenic mice were kindly provided
by Dr. Thomas Ludwig (Columbia University) and generated using the Cre-
ERT2 construct generated by Pierre Chambon at the Institute of Genetics and
Molecular Biology (University of Strasberg). Rag2/Il2rg/ mice were a
kind gift from the laboratory of Professor Richard Thompson (King’s Col-
lege London). CD45.11 congenic mice were a kind gift from the laboratory
of Professor Giovanna Lombardi (King’s College London). Mice were
housed in specific pathogenfree conditions. Male and female animals were
used in sex-matched and age-controlled experiments. Animals were used be-
tween 68 wk of age unless otherwise stated. B6-Mir142em2Card mice were
maintained at University College London under U.K. Home Office Project
License PPL: 70/8143
Study approval
All experiments were performed according to King’s College London and
national guidelines, under a U.K. Home Office Project License (PPL:70/
7869 to September 2018; P9720273E from September 2018).
Cell lines
293T cells (American Type Culture Collection) used for reporter assays
were maintained at 37C/5% CO2 in DMEM supplemented with 10% FCS,
2 mM L-glutamine, 10 mM HEPES, 1 nonessential amino acids, 1 mM so-
dium pyruvate 1 50 U/ml penicillin 1 50 mg/ml streptomycin (complete
DMEM [cDMEM]).
Nippostrongylus brasiliensis infection model
N. brasiliensis life cycle was maintained in male SpragueDawley rats ac-
cording to published methods (32). Infective L3 larvae were isolated from fe-
cal cultures through a Baermann apparatus and used for s.c. infection. Four-
hundred XL3 were injected per mouse into the left flank.
In vivo tamoxifen dosing protocol
A total of 100-mg doses of tamoxifen (Sigma-Aldrich no. 156738) diluted in
sunflower oil and warmed to 37C were administered i.p. once daily on 3
consecutive d to Mir142fl/flERT2Cre mice. Mice were monitored daily follow-
ing treatment. Successful deletion of miR-142 isoforms in peripheral lympho-
cyte populations using this protocol has previously been demonstrated (29).
In vivo activation of ILC2s by recombinant IL-33
C57BL/6J female mice were injected i.p. with 500 ng of recombinant murine
(rm) IL-33 (BioLegend) in 100 ml of PBS or PBS alone, once daily for 4
consecutive d. Animals were culled on day 5 and tissues harvested for ILC2
purification by FACS.
Generation of mixed BM chimeras
Rag2/Il2rg/ hosts were sublethally irradiated with 400 centigray given as
a split dose of 2  200 centigray 4 h apart. Twenty-four hours later, 2 
106 cells of total BM from donor mice was injected i.v. via the lateral caudal
vein in 150 ml PBS. Donor cells were prepared from female congenic B6
(CD45.11), WT C57BL/6J (CD45.21), and Mir142/ (CD45.21) mice,
mixed in the indicated ratios. The donor mixed cells were validated as hav-
ing the correct proportions of CD45.11/CD45.21 cells by flow cytometry.
Host animals were individually housed and placed on enrofloxacin (Baytril)
given in drinking water 48 h prior to irradiation and were maintained on
antibiotics for 2 wk after donor cell transfer. Six weeks posttransfer, host ani-
mals were culled, and tissues harvested for analysis.
Abs
Fluorophore-conjugated monoclonal Abs to the following mouse Ags were
used: CD3 (17A2), CD5 (53-7.3), Ly-6G (Gr-1), CD19 (1D3), CD11c
(N418), CD45 (30-F11), CD127 (A7R34), CD25 (PC61.5), Klrg1 (2F1),
Sca-1 (D7), Icos (15F9), a4b7 (DatK-32), Flt3 (A2F10), NK1.1 (PK136),
NKp46 (29A1.4), RORgt (B2D), T-bet (4B10), Gata3 (L50-823), IL-13
(eBio13A), IL-5 (TRFK5), IL-17A (TC11-18H10.1), Ki67 (SolA15), CD117
(2B8), pSTAT5(Y694), ST2 (RMST2-2), IL-25R (MUNC33), CD11b (M1/
70), Siglec-F (E50-2440), NGFR (ME20.4), Thy1.1 (HIS51), CTLA4
(UC10-4B9), IL-10 (JES5-16E3), PD-1 (29F.1A12), Tigit (GIGD7), CD45.1
(A20), and CD45.2 (104). Polyclonal Abs to Gfi1 (unconjugated) and against
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FIGURE 1. BM ILC2 progenitors are phenotypically altered and more prevalent in the absence of miR-142. (A) Representative flow cytometry plots dem-
onstrating an enriched pool of CD451LineageSca11c-Kit1Gata31CD1271CD251ST21 cells within the BM KLS (c-Kit1LineageSca-11) population of
Mir142/ mice compared with C57BL/6J (WT) controls. (B) Summary of proportion (%) of KLS population expressing (Figure legend continues)
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rabbit IgG (Alexa Fluor 488 conjugated) were also used. Fc receptor block-
ing was carried out with anti-CD16/32. The panel of lineage markers used to
identify peripheral lineage ILC in this study consisted of the above mono-
clonal Abs against CD3, CD5, CD19, Ly-6G, CD11c, CD11b, and Ter119.
When analyzing BM ILC and progenitor populations, the panel of lineage
markers consisted of the former in addition to NK1.1 in combination with a
fluorophore-conjugated mouse hematopoietic lineage Ab mixture (Thermo
Fisher Scientific) containing monoclonal Abs against CD3 (17A2), CD45R
(B220), CD11b (M1/70), Ter-119 (Ter-119), and Ly-6G (GR-1).
Tissue processing
Small intestinal lamina propria (siLP) and colonic lamina propria (cLP) leu-
kocytes were isolated as previously described (33) using collagenase-D (0.5
mg/ml) and Dispase-II (1.5 mg/ml) digestion with 10 mg/ml DNAse I in
HBSS without Mg21 or Ca21 1 2% FCS. A 4080% Percoll gradient sepa-
ration was used to isolate leukocyte enriched siLP and cLP samples. Lungs
were perfused with PBS via injection into the heart prior to harvest and lung
leukocytes were isolated by dicing lung tissue and digesting for 1 h at 37C
with 300 U/ml collagenase-II 1 150 mg/ml DNAse I in PBS without Mg21
or Ca21, followed by sample mashing through a 70-mm cell strainer into sin-
gle-cell suspension. BM was isolated by flushing the femur and tibia of both
hind legs per animal with PBS using a 27-gauge needle on to a 40-mm cell
strainer and mashing it through the membrane. Red cell removal was per-
formed on all samples using standard ACK lysis.
Flow cytometry and Sorting
Data were acquired using a BD LSRFortessa (BD Biosciences). Cells were
sorted using a BD FACS ARIA III (BD Biosciences) with the 355-nm laser
turned off. Only samples with a purity above 97% were used. Data analysis
was carried out using Flowjo software (TreeStar).
In vitro alarmin activation of ILC2s
siLP ILC2s were FACS purified from C57BL/6J female mice. Samples were
split and cultured in cDMEM with combinations of either recombinant hu-
man (rh) IL-7 1 rhIL-2 (10 ng/ml each) or rhIL-7 1 rhIL-2 1 rmIL-33 1
rmIL-25 (10 ng/ml each) (BioLegend) for 24 h at 37C/5% CO2 in U-bot-
tom 96-well plates. Following this, cells were recovered, washed twice in ice
cold PBS, and lysed in Qiazol (Qiagen) at 80C for later use.
Intracellular cytokine capture and exhaustion marker analysis
Intracellular cytokine capture for flow cytometric detection of IL-13 and IL-
5 was carried out by restimulating samples with 50 ng of PMA (Sigma-Al-
drich), 1 mM ionomycin (Sigma-Aldrich) in the presence of 1 mM monensin
for 4 h in cDMEM at 37C/5% CO2 . Unstimulated controls were cultured
in cDMEM with monensin only. Following viability and surface marker
staining, cells were fixed and permeabilized with the Foxp3 Staining Kit
(eBiosciences). For analysis of exhaustion markers, including IL-10, samples
were stimulated with 100 ng of PMA, 2 mM ionomycin for 3 h in the pres-
ence of 1 mM monensin, and 1 brefeldin-A (eBioscience) in cDMEM at
37C/5% CO2. Unstimulated samples were cultured with monensin and bre-
feldin-A only. Fixation was carried out for 10 min with methanol-free 2%
paraformaldehyde followed by permeabilization using the Foxp3 permeabili-
zation buffer (eBiosciences). Pd-1 and Tigit were carried out as extracellular
surface stains and Ctla4 was incorporated as both an extracellular and intra-
cellular stain.
STAT5 phosphorylation assay
Lamina propria leukocytes were isolated as described and rested for 1 h at
37C/5% CO2 in cDMEM prior to use. Prior to stimulation, samples were
stained for ILC2 and NCR1 ILC markers (CD45, lineage markers, Klrg1,
Sca-1, Icos, NK1.1, NKp46) using fluorophore-conjugated Abs. CD127,
typically used for ILC identification, was omitted to avoid the potential for
preactivation of IL-7Ra signaling pathways. Samples were stimulated with
rhIL-7 (10 ng/ml) or rhIL-2 (10 ng/ml) or left unstimulated. Viability stain-
ing was carried out 10 min prior to fixation. Samples were fixed at the de-
sired time point with prewarmed 4% formaldehyde for 10 min. Samples
were permeabilized with prechilled 100% methanol at 20C for 30 min.
Overnight intracellular staining for pSTAT5(Y694) was carried out at 4C
in PBS.
Quantitative PCR
FACS purified cells were sorted directly into QIAZOL (Qiagen), vortexed,
and frozen immediately on dry ice. Total lung tissue was washed in PBS
and placed directly into RLT buffer (Qiagen). Gut tissue was opened longitu-
dinally, scraped with a glass slide to remove mucus, and washed briefly in
PBS then placed in RLT buffer 1 10 mM/ml b-mercaptoethanol (Sigma-Al-
drich). Total RNA was isolated using the RNeasy Micro Kit or miRNeasy
Micro Kit (Qiagen), according to the manufacturer’s instruction. mRNA was
reverse transcribed to cDNA using random hexamers and the RevertAid First
Strand cDNA Synthesis Kit (Thermo Fisher Scientific). miRs were amplified
and reverse transcribed using the TaqMan Advanced miRNA cDNA Synthe-
sis Kit. Reactions for detection of Socs1, Gfi1, Il33, miR-142-3p, miR-142-
5p, Gapdh, and small nuclear RNA (snRNA) U6 were carried out in 10 ml
volumes using 2X Maxima probe/ROX qPCR Master Mix (Thermo Fisher
Scientific) and TaqMan real-time quantitative PCR (qPCR) assays with
FAM-labeled probes were performed. Reactions for detection of Dclk1, Il25,
and Gapdh were carried out in 10 ml volumes using Fast SYBR-Green Mix
(Applied Biosystems) Master Mix. Assays were analyzed with an ABI Prism
7900HT Real-Time PCR Instrument or ViiA 7 Real-Time PCR System (Ap-
plied Biosystems), where the Ct values were extracted. Relative gene expres-
sion and fold changes were calculated using the 2DDCt method.
miR-142target gene reporter assay
Reporter and miR expression plasmid constructs were designed and generated
as previously described (28). The 239T cells were plated into 12-well plates
at 7.3  104 cells per well, 24 h before transfection, and 3.28 ng of pcDNA-
tNGFR-poly(A)-PGK-Thy1.1 reporter plasmid containing either the WT or
mutated Mus musculus Gfi1 or Gata3 39 UTR and 1.17 mg pMY-miR-142-
IRES-PAC or pMY-IRES-PAC control plasmid was cotransfected into each
well using polyethyleneimine in quadruplicate. Reporter expression was deter-
mined 48 h after transfection by staining the cells with anti-NGFR and anti-
Thy1.1 followed by staining with DAPI for LIVE/DEAD cell discrimination.
Data are expressed as the ratio between the mean fluorescence intensity
(MFI) values obtained for CD271 (NGFR) and the Thy1.1 MFI values fol-
lowed by averaging of the quadruplicate measurements. The reporter expres-
sion values from samples transfected with the miR-142 expression vector
were normalized to the values of the samples transfected with the empty ex-
pression vector, which was set to 1.
RNA sequencing
RNA was extracted from c-Kit1LinSca11 (KLS) BM cells, and RNA-se-
quencing libraries were prepared using SMART-Seq v4 Ultra Low Input
RNA Kit for Sequencing (634891, Takara Bio, Kusatsu, Japan), and the
Nextera XT Library Preparation Kit (FC-131-1096; Illumina, San Diego,
CA). Libraries were then sequenced on an Illumina NextSeq 550 using the
150 Cycle High Output v2 Kit (FC-404-2002) with 2  75bp read length.
Bioinformatics analysis
Raw data to count matrix. ShortRead and Trimmomatic were used for
FASTQ file quality checks and to remove sequencing adapters. The FASTQ
files were aligned to mouse genome GRCm38/mm10 using Hisat2, whereas
the CD451LineageSca11c-Kit1Gata31CD1271CD251ST21 phenotype. (C) Total BM cell counts from both hind legs of WT and Mir142/ mice.
(D) Gating protocol for identification of aLP (Lineage-CD1271a4B7hi), ILC precursors (ILCp: LineageCD1271a4B7hiST2Pd-11Gata31CD25), and
ILC2p (Lineage-CD1271a4B7hiST21Pd-11/Gata31CD251) within the BM pool of WT and Mir142/ mice. Plots are pregated on live, single, CD451,
nonautofluorescent cells. (E) Total aLP, ILCp, and ILC2p cell counts per two hind legs of individual mice. (F) Percentage of ILCp and ILC2p populations
within the aLP pool. (G) Summary quantification of c-Kit expression by ILCp and ILC2p in WT and Mir142/ mice. (H) Representative flow cytometry plot
comparative overlays for c-Kit and Sca-1 expression by ILCp and ILC2p in WT and Mir142/ mice. (I) Summary quantification of ILC2p marker MFI (top)
and representative histogram overlays for expression of ST2, Gata3, CD25, Sca-1, and c-KIT by ILC2p across genotypes (bottom). Marker MFIs are for total
cells within the ILC2p gate, except for c-Kit MFI, which is the MFI of c-KIT1 ILC2p. In histograms, WT ILCp are shown as controls for ILC2p marker ex-
pression. For Gata3, a fluorescence minus one (FMO) gating control is shown. Data shown are representative of three similar, independent experiments with
n = 35 age and sex matched mice per genotype. Gate numbers represent the percent of the indicated parental gate. *p < 0.05, **p < 0.01, ***p < 0.001,
****p < 0.0001. n.s., nonsignificant.
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FIGURE 2. Peripheral ILC2 homeostasis at mucosal sites is critically regulated by miR-142. (A) Total number of ILC2s in the siLP, cLP, and lungs of
Mir142/ and C57BL/6J (WT) mice. (B) Representative flow cytometry plots of Gata3 and T-bet staining in siLP ILC2s. (Figure legend continues)
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SAMtools was used to remove low quality alignments and duplicates. Num-
ber of reads aligned to each gene were counted using Genomic Alignments.
Exploratory data analysis and filtering. The data matrix (p genes, n sam-
ples) was filtered for genes with mean of less than 3 to remove very low
count genes. Using low dimensional summaries of the data matrix (e.g., prin-
cipal components), the samples showed stratification with batches 1 and 2,
hence the data in each batch were normalized separately and the batch identi-
fier was adjusted for at the modeling level.
Model description. The expression for each gene was modeled as a negative
binomial variable, where the average difference between B6-Mir142em2Card
(miR-142 knockout) and WT groups in each batch 1 and 2 were estimated
as coefficients using a varying intercepts hierarchical modeling framework.
Pathway analysis. All analysis was implemented in R and Stan. Model fit
checks were performed using posterior predictive simulations. Pathway over-
representation and gene set enrichment analysis were performed using GO-
Stats and Generally Applicable Gene-set Enrichment.
The analysis source code is as follows: https://github.com/uhkniazi/
BRC_ILC_Joana_PID_21.
Statistical analysis
Normality testing was conducted using the ShapiroWilk test. Parametric
data were analyzed using two-tailed, t test with Welch correction. Mann
Whitney U test was performed on nonparametric data. Unless otherwise stat-
ed, the mean and SEM are represented in data visualization. Experiments
were not carried out under blinded conditions. Statistics analysis was carried
out in Prism v.8.0. Significance levels are expressed as p values where *p <
0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Results
BM ILC2 progenitors are phenotypically altered and more prevalent
in the absence of miR-142
miR-142 is highly expressed by cells of the hematopoietic lineage,
including hematopoietic stem cells which are often studied by isolat-
ing the c-Kit1 (Kit1) lineage Sca-11 population (KLS) found in
the BM. However, the KLS population is only enriched for hemato-
poietic stem cells and contains other cell types. Following analysis
of RNA-sequencing data generated from the KLS population of
mice with a genomic CRISPR-mediated deletion of miR-142
(B6-Mir142em2Card), our model predicted 118 genes to be differen-
tially overexpressed and 101 genes to be underexpressed in miR-
142deficient samples compared with controls; these gene sets were
enriched for gene ontology terms related to numerous aspects of im-
mune system regulation and function (Supplemental Fig. 1AC). In-
terestingly, markers of the ILC2 lineage were among the predicted
overexpressed transcripts (Supplemental Fig. 1D) among other genes
reported to contribute to an ILC2-like transcriptional signature
(Supplemental Fig. 1E) (14, 3439). Therefore, our data suggest
that the absence of miR-142 might lead to alterations to ILC2 devel-
opment from BM ILC precursor populations.
Using mice with a germline deletion of the entire Mir142 locus
(Mir142/) (29) we confirmed relative enrichment of ILC2-like
cells within the Mir142/ BM KLS pool (Fig. 1A, 1B). We next in-
vestigated BM ILC precursors, including ILCp and ILC2p popula-
tions found within the aLP progenitor population. There were no
differences in BM total cell number (Fig. 1C) or number of aLP
progenitor cells (Fig. 1D, 1E) between the genotypes. Likewise, no
alterations were found to the number of the ILCp precursor
population (LineageCD1271a4b71ST2Pd-11Gata31CD25)
(Fig. 1D, 1E). However, the proportion of ILCp within the aLP
population was decreased in Mir142/ mice in favor of an en-
hanced proportion of cells with an ILC2p phenotype (Linea-
geCD1271a4b71ST21Pd-11/Gata31CD251) (Fig. 1F), and
the number of ILC2p were increased overall (Fig. 1E). ILCp
from both genotypes were also positive for c-KIT and negative
for Sca-1, as previously described (40), whereas Mir142/
ILC2p demonstrated greatly enhanced expression of c-KIT, de-
spite most WT ILC2p being c-KIT/lo as expected (Fig. 1G,
1H) (3, 14, 15). This explained why an enhanced population of
ILC2-like cells were found to be present within the KLS popu-
lation of Mir142 deficient mice but not WT animals. Interest-
ingly, expression of surface markers for Mir142/ ILC2p were
greatly enhanced compared with WT ILC2p overall, despite
comparable Gata3 expression between the genotypes (Fig. 1I).
Based on these data, we conclude that isoforms of miR-142 play
critical roles in defining the phenotype of ILC2p in the BM and
may play important roles in restricting the developmental program
of the ILC2p/ILC2 lineage.
miR-142 controls ILC2 homeostasis at peripheral mucosal tissue
sites
In peripheral tissues, ILC2s are enriched at mucosal barrier sites in-
cluding siLP, cLP, and lung. In Mir142/ mice, ILC2 numbers
were unchanged in the siLP, whereas in the cLP and lung, there
were fewer ILC2s (Fig. 2A, Supplemental Fig. 2A, 2B). These find-
ings were robust in the face of different gating methods used to
identify ILC2s (Supplemental Fig. 2C, 2D). Mir142/ ILC2s re-
tained high levels of Gata3 expression, without coexpression of
T-bet (Fig. 2B, 2C) or RORgt (Supplemental Fig. 2C), supporting
their identity as ILC2s. After analysis ex vivo, a striking observation
was that Mir142/ ILC2s in these peripheral sites displayed a vastly
altered cell surface phenotype compared with WT controls, match-
ing observations in BM Mir142/ ILC2p (Fig. 2DF, Supplemental
Fig. 2E). This phenotype was largely characterized by enhanced sur-
face expression of numerous ILC2 markers including CD25, Sca-1,
Klrg1, and alarmin receptors ST2 (IL-33R) and IL-25R, whereas
CD127 was downregulated compared with controls. An exception
was a reduced expression of Icos by siLP Mir142/ILC2s (Fig.
2D), despite significant overexpression of Icos by cLP and lung
Mir142/ ILC2s (Fig. 2E, 2F, Supplemental Fig. 2E). None of the
39UTR regions of the transcripts for these markers were identified
as direct targets of miR-142 isoforms (DIANA microT-CDS, Tar-
getScanMouse v7.1). Increase of these markers on ILC2s was there-
fore not likely to be explained by direct gene derepression in the
absence of miR-142.
Interestingly, although Klrg1 is not highly expressed by lung
ILC2s at immunological baseline (8), the majority of ILC2s in
Mir142/ lungs were Klrg11 (Fig. 2G, 2H) and significantly over-
expressed Klrg1 compared with control Klrg11 ILC2s (Fig. 2F).
Given the alterations to alarmin receptor expression, along with an
enhanced expression of Klrg1, we therefore questioned whether the
ILC2 phenotype of Mir142/ mice could be explained by a
Quadrant numbers indicate percent of the ILC2 parent population. (C) Summary of Gata3 staining MFI of WT and Mir142/ lung ILC2s. (D) Representative
histograms (top) and summary MFI (bottom) of ILC2 phenotypic markers including ICOS, CD25, Sca-1, CD127, Klrg1, ST2, and IL-25R for WT and
Mir142/ siLP ILC2s. (E) As for (D) but for cLP ILC2s. (F) As for (D) but for lung ILC2s. (G) Differential analysis of ST2 and IL-25R expression by
Klrg1 and Klrg11 lung ILC2, identified as CD451LineageCD1271NK1.1-NKp46-CD251Icos1 cells in C57BL/6J and Mir142/ mice. Gate numbers pre-
sent percentage of parental gate. (H) Percentage of lung ILC2s expressing Klrg1. (I) Quantification of data represented in (G) for percentage of total Klrg1
(top) and Klrg11 (bottom) lung ILC2s expressing combinations of ST2 and IL-25R. Graphs depict mean ± SEM. (A and B) Welch t test and (D) unpaired t
test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data are representative of three independent experiments with between n = 35 age- and sex-
matched mice per genotype. n.s., nonsignificant difference.
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FIGURE 3. miR-142deficient ILC2s are defective in response to N. brasiliensis infection. (A) Representative flow cytometry plots of lung ILC2s Ki-67
staining, directly ex vivo. Gate numbers represent the proportion (%) of ILC2s that are Ki671. (B) Summary for percent of lung (Figure legend continues)
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preferential increase in iILC2s. However, differential analysis of the
Klrg1 and Klrg11 lung ILC2 populations revealed that the predomi-
nant IL-25R-expressing population in Mir142/ mice was Klrg1
ILC2s, not Klrg11 cells (Fig. 2G, 2I). Additionally, the IL-
25R1ST2 ILC2 population observed only in Mir142/ lungs was
found only in the Klrg1 population; Klrg11 ILC2s were highly
ST21, whereas iILC2s are reported to be ST2/lo. Therefore, the ef-
fects on ILC2s observed in these mice were not obviously explained
by a selective expansion of conventional Klrg1hi or IL-25R1 iILC2s.
miR-142deficient ILC2s are defective in response to N. brasiliensis
infection
Given the altered phenotypic profile of Mir142/ ILC2s, we investi-
gated whether ILC2 effector functions would also be altered under
conditions known to activate the cells in vivo. Damage by tissue mi-
grating helminths at barrier sites is a critical inducer of alarmin release
from epithelial cells and ILC2s are established as central innate effec-
tors of the antihelminth type 2 immune response. Therefore, we used
N. brasiliensis infection as a model to probe these responses in vivo.
Adult worms were found in the small intestine of all infected
mice. Parasite burden of the small intestine at day 5 postinfection
was not significantly different between Mir142/ and WT geno-
types. (Supplemental Fig. 3A). The total number of CD451 leuko-
cytes in the lungs of Mir142/ mice was significantly lower than in
control lungs (Supplemental Fig. 3B). ILC2 numbers in the lung
were not altered by N. brasiliensis infection at the time point investi-
gated in either genotype (Supplemental Fig. 3C). However, prolifer-
ative responses of Mir142/ ILC2s were significantly impaired
following infection compared with WT ILC2s from infected mice,
which significantly upregulated Ki-67 compared with ILC2s from
infection naive WT lungs (Fig. 3A, 3B). ST2 and IL-25R expression
were enhanced on WT ILC2s in response to infection, as expected
(Fig. 3C, 3D, Supplemental Fig. 3D, 3E). However, despite the ele-
vated expression of these receptors by Mir142/ ILC2s from naive
mice, ST2 expression was further enhanced by Mir142/ ILC2s in
response to infection (Fig. 3C, 3D) as was Klrg1 (Fig. 3E, 3F). This
was not the case for IL-25R (Supplemental Fig. 3D, 3E). Examina-
tion of ILC2 effector cytokine responses revealed that WT ILC2s
highly expressed both IL-5 and IL-13 (Fig. 3G, 3H, Supplemental
Fig. 3F) and significantly upregulated the amount of IL-13 produced
following N. brasiliensis infection (Fig. 3I). However, Mir142/
ILC2s were inhibited from effector cytokine production at both
baseline and in response to infection (Fig. 3GI). This was not in
favor of an enhanced production of IL-17A, which was also lacking
in Mir142/ mice (Fig. 3J, 3K). Recently, a Runx-dependent ex-
haustion phenotype for ILC2s has been described, characterized by
a lack of responsiveness to alarmin signaling (41). However, analy-
sis of Pd-1, Tigit, IL-10, and Ctla4 expression by lung ILC2s re-
vealed no obvious differences between genotypes (Supplemental
Fig. 3G, 3H), suggesting that a prior exhausted state does not under-
lie nonresponsiveness of lung Mir142/ ILC2s to N. brasiliensis
infection.
These data reveal that because of defective effector activity,
Mir142/ ILC2s are unable to appropriately respond to parasitic
helminth infection in vivo. Expression of miR-142 isoforms by
ILC2s is therefore an essential component of the mechanics of the
innate arm of type 2 immunity.
Cell-intrinsic expression of miR-142 isoforms critically regulates
ILC2 phenotype and function
To evaluate whether absence of cell-intrinsic miR-142 expression in
miR-142deficient ILC2s was responsible for our observations, we
purified lung ILC2s and BM ILC2p from WT mice and analyzed
expression of miR-142-3p and miR-142-5p isoforms by qPCR (Fig.
4A). Cells were isolated from animals at steady state (treated with
PBS) and from IL-33treated mice, as a useful model of ILC2 acti-
vation in vivo. Expression of miR-142-3p and miR-142-5p isoforms
was observed in mature lung ILC2s from both PBS and IL-33-
treated mice, and BM ILC2p following IL-33 treatment. Only miR-
142-3p expression was observed in BM ILC2p from PBS-treated
mice (Fig. 4A). Overall, miR-142-3p appeared to be slightly more
abundant than miR-142-5p in ILC2p and lung ILC2s. A small, non-
significant trend toward reduced miR-142-3p expression was appar-
ent following IL-33 treatment. Both miR-142-3p and miR-142-5p
were also detected in siLP ILC2s (Fig. 4B). Following short term
in vitro culture (24 h) in the presence of IL-2, IL-7, IL-25, IL-33,
and miR-142 isoform expression levels were reduced compared
with cells cultured in IL-2 and IL-7 alone (Fig. 4B).
Given the upregulation of markers associated with activation state
of the cells (9) by Mir142/ ILC2s and ILC2p (Fig. 1, Fig. 2), we
questioned whether stimuli responsible for steady-state activation of
the cells, such as IL-25 (42) might be enhanced at mucosal sites in
these mice. However, Mir142/ mucosal tissues did not express
greater transcript abundance for Il25 or the Tuft cell marker Dclk1
(Fig. 4C). Expression of transcripts for IL-33 was also unaltered be-
tween genotypes (Fig. 4C). Next, to determine whether the altered
peripheral ILC2 phenotype in Mir142/ mice was solely develop-
mentally programmed, we used a tamoxifen (TXN)-inducible model
of Mir142 deletion (Mir142fl/flERT2Cre) (29). Prior to TXN treatment,
both control (Mir142fl/flERT2CreWT/WT) and Mir142fl/flERT2CreWT/1
adult littermates had the same composition of ILC subsets and ILC
phenotypes, as expected (data not shown). However, following TXN
administration, peripheral Mir142fl/flERT2CreWT/1 ILC2s displayed an
altered phenotype equivalent to Mir142/ ILC2s (Supplemental Fig.
4A, 4B). This suggests that in WT ILC2s, miR-142 isoforms actively
maintain the ILC2 state in the periphery. To address whether this dis-
ruption of ILC2 homeostasis was dependent on miR-142 expression
in lymphocytes known to interact with ILCs (43, 44), we used mice
with Mir142 deletion only in T cells (Mir142fl/flCd4Cre1). ILC2s in
these mice were normal with no evidence of the alterations displayed
in either constitutive or temporal models of miR-142 deletion
(Supplemental Fig. 4C, 4D). We next asked whether the observed
phenotype was because deletion of miR-142 solely in the innate im-
mune compartment. Rag1/Mir142/ retained the altered ILC2 phe-
notype observed in Mir142/ mice (Supplemental Fig. 4E, 4F).
To further probe the case for cell-intrinsic regulation of ILC2s by
miR-142 isoforms, we generated mixed BM chimeras by transfer-
ring mixtures of congenic (CD45.11) B6, WT (CD45.21) C57BL/
ILC2s expressing Ki-67. (C) Representative histogram overlay of ST2 staining on lung ST21 ILC2s. ST2 Fluorescence minus one (FMO) staining control is
indicated by the dotted line. (D) MFI of ST2 staining on total ST21 lung ILC2s. (E) As for (C) but for Klrg1 staining. (F) As for (D) but for Klrg1 MFI. (G)
Representative flow cytometry plots for IL-5 and IL-13 expression by lung ILC2s following sample restimulation ex vivo. Quadrant numbers represent the
percent of the ILC2s parental gate. (H) Percent of lung ILC2s expressing combinations of IL-5 and IL-13. (I) IL-13 MFI of total IL-131 ILC2s. (J) Percent
of lung ILC2s expressing IL-17A. (K) Summary for percent of lung ILC2s expressing IL-17A. n = 6 sex- and age-matched mice for N. brasiliensisinfected
groups and n = 3 sex- and age-matched mice for naive (uninfected) groups. Analysis of cells from infected animals was done at day 5 postinfection. *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s., nonsignificant difference.
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FIGURE 4. Cell-intrinsic expression of miR-142 isoforms critically regulates ILC2 phenotype and function. (A) Expressions of miR-142-3p and miR-142-
5p (relative to snRNA U6) in BM ILC2p and lung ILC2s of female C57BL/6J mice treated with PBS or rmIL-33. Joined data points indicate values from the
same samples. (B, left) Expressions of miR-142-3p and miR-142-5p (relative to snRNA U6) in siLP ILC2s cultured for 24 h in (Figure legend continues)
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6J, and Mir142/ (CD45.21) BM into irradiated alymphoid Rag2/1
Il2rg/ hosts as indicated (Fig. 4D). Adoptive transfer of Mir142/
BM only, was carried out as a control for development of the
Mir142/ ILC2 phenotype in the absence of competing WT cells.
Rag2/Il2rg/ are widely referred to as “ILC deficient.” However,
few studies acknowledge that this strain does retain a small number of
residual CD45.21LineageCD1271, immature ILC-like cells, some of
which are ILC2-like cells based on Gata3hi-staining expression and ab-
sence of RORgt expression (Fig. 4E). However, the absence of
markers of ILC2 maturity such as ST2 and CD25 (Fig. 4E) enabled
sufficient gating of mature donor ILC2s in animals receiving BM
transfers (Fig. 4FH). In hosts receiving CD45.11 B6/CD45.21 B6
cells (the WT control donor group), the phenotype of CD45.11 and
CD45.21 ILC2s was equivalent 6 wk posttransfer, as judged by ana-
lyzing normalized marker staining MFIs (CD45.2/CD45.1) (Fig. 4F,
4I). In contrast, despite the presence of CD45.11 WT cells, CD45.21
ILC2s in animals receiving CD45.11 B6/CD45.21 Mir142/-mixed
BM displayed a highly altered phenotypic profile based on marker
staining MFI (Fig. 4G, 4I). This phenotype was comparable with
ILC2s, which developed in hosts receiving Mir142/ BM only (Fig.
4H). Interestingly, CD45.21 Mir142/ ILC2s in hosts receiving
CD45.11 B6/CD45.21 Mir142/ donor cells demonstrated slightly el-
evated expression of Gata3 and CD127, comparative with congenic
CD45.11 ILC2s (Fig. 4I). It is possible that these observations re-
flected homeostatic selection processes related to survival of Mir142/
ILC2s in the presence of competing WT cells. In hosts receiving
CD45.11 B6/CD45.21 B6 BM, the proportion of CD45.11 and
CD45.21 ILC2s within the total samples were equivalent (Fig. 4J).
This was despite a significant bias for engraftment of CD45.21 total
cells overall (Fig. 4K); a recognized phenomenon in mixed CD45.11/
CD45.21 reconstitution experiments with WT genotypes (45). Howev-
er, in hosts receiving CD45.11 B6/CD45.21 Mir142/-mixed cells,
the expected CD45.21 engraftment bias was reversed in favor of
CD45.11 cells (Fig. 4K), indicating that Mir142/ cells display severe
disadvantages in either their development or the process of engraft-
ment, in the presence of Mir142 replete competitors. This observation
was also reflected by a significantly lower proportion of CD45.21
Mir142/ ILC2s overall, compared with CD45.11 WT control cells
(Fig. 4J). Importantly, despite enhanced Gata3 expression, CD45.21
Mir142/ ILC2s from mixed chimeras displayed severely restricted
expression of type 2 effector cytokines, despite good expression by
CD45.11 WT ILC2s when stimulated with PMA/ionomycin ex vivo
(Fig. 4L).
These data demonstrate that ILC2s and ILC2ps express mature
miR-142 isoforms in mice, and strongly support the hypothesis that
these regulatory molecules play critical, cell-intrinsic roles in estab-
lishing cellular phenotypes and effector functions of the ILC2
lineage.
Optimal c-chain cytokine signaling is mediated by miR-142-5p
repression of Socs1 in ILC2s
Socs1 is a reported miR-142-5p target (25, 46, 47) and Socs1 over-
expression in ILC2s has previously been associated with defective
cytokine production (48). Indeed, Socs1 transcript levels were in-
creased. In Mir142/ ILC2s, consistent with a recent report investi-
gating the role of miR-142 in ILC1s (31) (Fig. 5A, 5B). Socs1
inhibits Jak/Stat signaling pathways and correspondingly, Mir142/
ILC2s demonstrated significantly lower induction of pStat5(Y694)
following ex vivo stimulation with IL-7, compared with controls
(Fig. 5C, 5D). IL-7 signaling via Stat5 plays a critical role in main-
tenance of peripheral ILC2 populations and interestingly, lower
pStat5 was also apparent in unstimulated Mir142/ ILC2s (Fig. 5C,
5D). This may explain the observation that Mir142/ ILC2s dem-
onstrated significantly reduced Ki-67 expression, indicating a re-
duced proliferative capacity of the cells (Fig. 3A, 3B, Fig. 5E, 5F).
However, IL-7Ra (CD127) is also decreased on Mir142/ ILC2s
(Fig. 2) and might underlie reduced Stat5 activation. Therefore, we
also assessed the capacity of Mir142/ ILC2s to respond to IL-2
stimulation, as Mir142/ ILC2s and progenitors overexpress the IL-
2R subunit CD25 (IL-2Ra) (Fig. 1I, Fig. 2DF). However, they
were not deficient for CD122 (IL-2Rb) (Fig. 5G) or CD132 (IL-
2Rg) (Fig. 5H). Nonetheless, whereas control siLP ILC2s demon-
strated a rapid and robust Stat5 phosphorylation in response to IL-2
stimulation ex vivo, responsiveness to IL-2 was significantly inhib-
ited in Mir142/ ILC2s (Fig. 5I, 5J). These data indicate that gc-cy-
tokine signaling in Mir142/ ILC2s is defective. A possible
explanation for this is that under normal settings, miR-142-5p acts
to restrict Socs1 expression, to support ILC2 homeostasis and prolif-
eration at baseline.
Growth factor independent 1 is regulated by miR-142-3p in ILC2s
Enhanced expression of Socs1 by Mir142/ ILC2s could account
for the proliferative and effector defects observed. However, it could
not easily account for the altered phenotypic profile of ILC2s or the
augmentation in ILC2p numbers in the absence of Mir142. We
therefore considered whether essential transcription factors relevant
to ILC2 development and activation might be critically regulated by
miR-142 isoforms. Among the transcription factors known to play
critical roles in ILC2 development and function, we identified puta-
tive 39UTR targets for miR-142-5p and miR-142-3p in Gata3 (3, 4)
and Gfi1 (5), respectively (Fig. 6A, 6B). The minimum free energy
value determined using RNAhybrid (49) was quite poor for Gata3
and miR-142-5p (10.5 kcal/mol), predicting a relatively weak sec-
ondary structure for the interaction (Fig. 6A), whereas the interac-
tion between Gfi1 and miR-142-3p was predicted to be much more
stable (18.5 kcal/mol) (Fig. 6B). Additionally, analysis of a pub-
lished AGO2-CLIP dataset identifies Gfi1 as a potential target of
vitro with recombinant IL-2 1 IL-7 only, or IL-2 1 IL-7 1 IL-25 1 IL-33. Joined data points indicate paired samples from cells isolated from individual
mice. (B, right) Fold change of miR-142 expression levels in IL-2 1 IL-7 1 IL-25 1 IL-33treated ILC2s normalized to values of IL-2 1 IL-7treated cells.
(C) Expression of Dclk1, Il25, and Il33, relative to Gapdh expression, determined by qPCR using cDNA from total RNA samples extracted from tissue ly-
sates prepared from small intestine (SI), colon, and lung samples from C57BL/6J (WT) and Mir142/ mice. Animals were age- and sex-matched, n = 5 per ge-
notype, and size and physiological location of each tissue sample was standardized between biological replicates and across genotypes. (D) Schematic detailing
experimental setup of mixed BM chimera generation in irradiated (black lightning bolt) Rag2/Il2rg/ host mice. (E) Gating for lung ILC2s in nonirradiated
CD45.21 Rag2/Il2rg/ mice. (F) As for (E) but for irradiated Rag2/Il2rg/ host mice receiving mixed total BM from congenic CD45.11 B6 and CD45.21
C57BL/6J donors. (G) As for (F) but donor cells were from CD45.11 B6 and CD45.21 Mir142/ mice. (H) As for (F) but donor cells were from CD45.21
Mir142/ mice only. (I) Summary of flow cytometry staining MFI values for CD45.21 ILC2s expression of indicated markers, normalized to congenic
CD45.11 ILC2s within the same host. (J) CD45.11 and CD45.21 ILC2s expressed as proportions of total, live, single lung cells from Rag2/Il2rg/ hosts re-
ceiving the indicated donor cell mixtures. (K) As for (J) but for proportion of total CD45.11 and CD45.21 cells. (L) Representative flow cytometry plots for ex-
pression of IL-13 and IL-5 by lung CD45.11 B6 (WT) and CD45.21 Mir142/ ILC2s from Rag2/Il2rg/ hosts receiving mixed total BM of the two
genotypes. n = 57 mice per experiment. *p < 0.05, **p < 0.01, ****p < 0.0001. n.s. nonsignificant.
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miR-142-3p in lymphocytes (50). Correspondingly, Gata3 expres-
sion in purified siLP ILC2s was not enhanced in Mir142/ ILC2s
relative to WT ILC2s, whereas Gfi1 demonstrated increased expres-
sion levels (Fig. 6CE). Results of a flow cytometric reporter assay
for the identification of miR-142 targets (28), also revealed that the
putative miR-142-5p site in the Gata3 39UTR was not a true target
site (Fig. 6F). This was supported by the prior demonstration of
comparable levels of Gata3 expression in ILC2s and ILC2p between
genotypes (Fig. 1I, Fig. 2B, 2C). In contrast, expression of Gfi1 was
greater in Mir142/ ILC2 relative to WT controls (Fig. 6H) and
reporter assay analysis, including seed-site targeted mutagenesis, sup-
ported the putative Gfi1 binding site as a valid target of miR-142-3p.
Discussion
In this study, we reveal critical, cell-intrinsic roles for miR-142 iso-
forms in the regulation of ILC2 homeostasis and function. Previous-
ly, miR-155, miR-146a, and the miR-1792 cluster have also been
shown to play important roles in ILC2 function (48, 51, 52). These
include protection from apoptosis and expansion of ILC2s during
FIGURE 5. Optimal g-chain cytokine signaling is mediated by the repression of Socs1 by miR-142-5p in ILC2s. (A) Expression of Socs1 relative to Gapdh
in ILC2s (CD451lineageCD1271NK1.1NKp46Klrg11Sca-11) from siLP. (B) Fold change of Socs1 in Mir142/ compared with WT ILC2s for data
from (A). (C) Representative histograms for pStat5(Y694) induction by either unstimulated siLP ILC2s, or siLP ILC2s following ex vivo exposure to IL-7
(10 ng/ml) for 30 min. (D) Summary data for pStat5(Y694) induction by either unstimulated siLP ILC2s, or siLP ILC2s following ex vivo exposure to IL-7
for the time points indicated. Zero minutes indicates unstimulated samples. (E) Representative flow cytometry plots for Ki-67 staining in siLP ILC2s. Gate
numbers represent percentage of parental ILC2 gate. (F, left) Percent of Ki-671 ILC2s as in (E) and (F, right) enumeration of Ki-671 siLP ILC2s as in (E).
(G) MFI of CD122 (IL-2Rb) staining on siLP ILC2s. (H) as for (G) but for CD132 (IL-2Rg) staining. (I) As for (C) but following ex vivo exposure to IL-2
(10 ng/ml) for 60 min. (J) As for (D) but following ex vivo exposure to IL-2 for the time points indicated. Data (A and B) represent samples from three inde-
pendent experiments of pooled biological siLP replicates in which n = between 35 mice per independent repeat. Paired Mir142/ and WT samples from
each independent experiment are indicated by connected data points. Data (CJ) carried out with between n = 35 sex- and age-matched mice per genotype
and/or treatment group. Data (EG) representative of results of two independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n.s.
nonsignificant.
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FIGURE 6. Gata3 is not targeted by miR-142; however, Gfi1 is a target of miR-142-3p in ILC2s. (A) In silico identification of a predicted miR-142-5p tar-
get site in the 39UTR of the Mus musculus Gata3 mRNA transcript. Schematic from RNAhybrid analysis used to determine the (Figure legend continues)
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chronic and acute airway allergen exposure, in addition to regulating
ILC2 proliferation and expression of effector cytokines and Gata3
expression following exposure to IL-33. Interestingly, comparison
of the miR transcriptome for Th2 and ILC2s demonstrates that al-
though a large amount of overlap occurs between these cell types, a
significant degree of difference is also apparent (48). miR-142 is
highly expressed in T cells and its constitutive ablation results in a
defect in peripheral T cell numbers through an as yet unknown
mechanism (18, 19), putatively related to cell cycling defects in thy-
mocyte precursors. In contrast, our data indicate that although the
absence of miR-142 results in ILC2 deficiency in sites such as the
lung and cLP (alongside a general reduction in CD451 leukocyte
numbers in peripheral tissues, as seen in the lung; Supplemental
Fig. 3B), ILC2 numbers in the siLP are unaffected, perhaps sugges-
tive of differential regulatory actions of miR-142 in ILC2s compared
with T cells.
It is possible that the combination of a biased production of
ILC2p in Mir142/ animals, coupled with the suggestion that
ILC2p preferentially migrate to the intestinal lamina propria during
the steady state (3) may underlie this unexpected observation. BM
ILC2p already express the MAdCAM-1 receptor, a4b7 integrin, as
well as CCR9, which is important for homing to the small intestine,
which selectively expresses the CCR9 ligand CCL25. A severely re-
stricted responsiveness to homeostatic survival factors such as IL-7
and IL-2 (likely underling dysfunctional baseline proliferative re-
sponses of ILC2s in Mir142/ mice) may then result in comparable
overall numbers of the cells at this site with WT controls. This is
despite a theoretically greater influx of cells in Mir142/ mice. Fur-
ther work is required to understand this observation fully. Mir142-
deficient ILC2s may serve as a useful model to investigate the na-
ture of ILC trafficking, as well as the maintenance of mature popu-
lations of ILC2s in the periphery.
Deletion of Mir142 leads to accumulation of ILC2s with an altered
phenotype. Analysis of BM ILC2p indicates that in Mir142/ mice,
the altered phenotype of peripheral ILC2s may be developmental in
origin because of enhanced expression of markers such as CD25 and
ST2. However, data from temporally deleted Mir142fl/flERT2CreWT/1
animals suggested that miR-142 also regulates this phenotype postde-
velopmentally in the periphery. Therefore, miR-142 isoform expres-
sion may be critical both during development and for homeostatic
maintenance of ILC2s. It is possible that the altered phenotype of
Mir142/ ILC2s may be related to a heightened sensitivity to tissue
signals such as IL-33 and IL-25 in vivo. This could be because of ei-
ther directly mediated enhanced expression of miR-142-3p target
Gfi1, which positively regulates these receptors (5), or indirect effects
of Gfi1 on Gata3 protein stability or activity (53). This hypothesis is
consistent with previous studies identifying a role for IL-33 and IL-25
in the steady-state activation and function of ILC2s at tissue specific
sites (42, 54, 55). Our findings suggest that miR-142 regulates aspects
of the phenotype of ILC2s associated with their activation state. This
is consistent with the reported anti-inflammatory regulatory actions of
miR-142 in other lymphocyte lineages (23, 30) and with the indica-
tion of a negative correlation between ILC2 exposure to activation
stimuli (i.e., alarmins) and miR-142 isoform expression levels. Induc-
ible deletion of miR-142 from mature, peripheral ILC2 populations
also indicates that ILC2 responses can be modulated postdevelopmen-
tally via the manipulation of miR-142 expression. This information is
potentially highly relevant in the various settings in which the modu-
lation of ILC2 responses might be an attractive therapeutic target,
such as in parasite infections, allergic disease, or asthma. More recent-
ly, attention has also turned to understanding the presence of ILC2s
within the setting of the tumor microenvironment, and investigation
of whether the roles played by these cells during antitumor immunity
may be harnessed or repurposed therapeutically (56). Although further
work will be required to investigate this prospect, manipulation of
miR-142 isoforms and/or miR-142regulated pathways in ILC2s may
hold promise for development of novel immunotherapeutics benefit-
ing the field of immuno-oncology.
Despite an altered cell surface phenotype reminiscent of an en-
hanced activation state, Mir142/ ILC2s were severely defective in
their proliferative and effector responses during N. brasiliensis infec-
tion, as well as at baseline. Analysis of exhaustion and inhibitory
checkpoint receptors (41, 57) did not suggest that Mir142/ ILC2s
present an advanced state of cellular exhaustion overall. It is possi-
ble that high-level expression of Klrg1 by miR-142deficient ILC2s
may have contributed to the nonresponsiveness of these cells
in vivo, as in human skin ILC2s, the interaction between Klrg1 and
its ligand E-Cadherin is thought to be inhibitory (58). In addition,
Mir142/ ILC2s did not appear to selectively represent iILC2s,
which are known to potently produce cytokines such as IL-13 and
IL-17A following activation with IL-25 and also highly express
Klrg1 (10). This suggests that increased expression of Klrg1 alone
does not sufficiently explain ILC2 nonresponsiveness to in vivo acti-
vation stimuli. Alternatively, regulation of Socs1 by miR-142-5p
may have critical relevance with regards to dysregulated ILC2 effec-
tor function. Previously it was shown that upregulation of Socs1 fol-
lowing miR-19 deletion was partially responsible for the inhibition
of ILC2 type 2 cytokine production (48) and a similar function for
miR-19regulated Socs1 has also been reported for Th2 cells (59).
Additionally, the reliance of ILC2s, and other ILC subsets, on the
minimum free energy (mfe) for the interaction between the Gata3 39UTR predicted target site and miR-142-5p. (B) As for (A) but for the predicted target site
between miR-142-3p and the 39UTR of Mus musculus Gfi1. (C) Expression of Gata3 relative to Gapdh in FACS purified ILC2s (CD451Linea-
geCD1271NK1.1NKp46Klrg11Sca-11) isolated from the siLP of C57BL/6J (WT) and Mir142/ mice. Gata3-relative expression of purified siLP
NCR1 ILCs (CD451LineageCD1271NK1.11NKp461) from WT mice was included as a biological control for the assay. (D) As for (C) but for Gfi1.
(E) Data from (C) and (D) expressed as Mir142/ ILC2 Gata3 or Gfi1 fold change using WT values to normalize expression. (F) miR-142 isoforms do not
directly target the predicated Gata3 seed site identified in (A). Expression of an NGFR reporter gene that has either the WT or a mutated (Mut) Gata3 39
UTR miR-142-5p binding site inserted in the presence of an empty control (pMY-IRES-PAC) or miR-142 expression vector (pMY-IRES-Mir142-PAC) in
HEK293T cells. A vector with a perfect target site for Mir142-mediated knockdown (miR-142 perfect target) was used as a positive control for miR-
142mediated repression in the assay. (G) Representative histograms for siLP ILC2s (CD451LineageCD1271NK1.1NKp461Klrg11Sca-11) and non-
ILC2 ILCs (CD451LineageCD1271Klrg1) staining with rabbit anti-mouse anti-Gfi1 followed by secondary staining with Alexa Fluor 488conjugated
goat anti-rabbit IgG. MFI values for each population are indicated. A secondary Ab only sample (omitting rabbit anti-mouse anti-Gfi1 staining) was the nega-
tive staining control. (H) Targeting of WT Gfi1 mRNA 39UTR by miR-142 in HEK293T cells. Mutation (Mut) of the miR-142-3p seed site of Gfi1 prevents
miR-142mediated reporter knockdown. Data in (C)(E): samples from three independent experiments of pooled biological siLP replicates in which n = be-
tween 35 mice per independent repeat. Paired Mir142/ and Mir1421/1 samples from each independent experiment are indicated by connected data points.
Data in (F) and (H): two independent experiments and n = 4 replicates per construct, per treatment group. Paired data points represent samples analyzed from
independent experiment runs. Bar graphs depict mean ± SEM. Student t test, *p < 0.05, ****p < 0.0001. n.s., nonsignificant.
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expression and function of Stat5 for the optimal expression of signa-
ture cytokine production, and the role of Stat5 in the activation of
the transcription of type 2 cytokine loci have been described (60,
61). Socs1 is a critical inhibitor of Stat5 activation and signaling,
and as Mir142/ ILC2s clearly demonstrate a profound defect in
Stat5 activation mediated via gc-cytokine signals, this would explain
why Mir142/ are defective in IL-13 and IL-5 cytokine production.
Additionally, Stat5 signaling mediated by IL-7 and/or IL-2 is known
to mediate ILC2 homeostatic accumulation (60). Overexpression of
Socs1 may therefore underlie the proliferative defects demonstrated
by Mir142/ ILC2s, but further investigation is required to fully
confirm these hypotheses.
This study indicates that Gfi1 and Socs1 are direct targets of
miR-142 isoforms in ILC2s. Interestingly, Gfi1 is already preferen-
tially expressed highly in ILC2s. Therefore, one interpretation of our
model may be that miR142-3p regulates optimal expression of Gfi1
by ILC2s during homeostasis. This may be sufficient to direct the
appropriate pathways of the ILC2 developmental program, as well
as to restrict over expression of alarmin receptors and maintain the
resting state of ILC2s prior to alarmin induced ILC2 activation.
That miR-142-3p appeared to be the most highly expressed
miR-142 isoform in ILC2ps at baseline may also suggest that regu-
lation of optimal Gfi1 expression during ILC2 development is par-
ticularly important for correct and appropriate differentiation of this
lineage.
These findings reveal novel, to our knowledge, critical molecular
pathways which govern the homeostasis and functional activity of
ILC2s. These pathways have the potential to be manipulated and ex-
ploited for therapeutic gain.
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